Black and white image of fine powder particles on the left giving way to spherical droplets drifting to the right, against a dark background.

Aerosol science for orally inhaled and nasal drug products

We measure how individual particles behave under airway conditions and model the formulation design space on those measurements, so you can identify the formulations capable of meeting your target product profile before committing laboratory time.

Contact usSee how it works

The formulation design space

An inhaled or nasal formulation has more variables than any laboratory can cover: material properties, particle size distribution, and the temperature and humidity the aerosol meets in the airway. We map that space in silico from measured particle physics, so you can identify the candidates capable of meeting your target product profile before committing laboratory time.

Who we help

Biotechs.

For teams taking a molecule into inhaled or nasal delivery, we provide the measurement and aerosol physics behind formulation decisions, with a written rationale for the approach chosen.

Pharma.

For innovator and generic programmes, we help narrow formulation options before laboratory time is committed, and explain results that do not behave as expected.

CROs and CDMOs.

We add single-particle measurement and aerosol modelling to the programmes you run, working alongside your team. We do not offer analytical testing or manufacture. Our work is delivered under the Microsol name, and co-branding is welcome.

Device makers.

We measure how candidate formulations behave once aerosolised, under airway conditions, giving device teams realistic formulation data to work with.

Applications

  • Inhaled biologics
  • Dry powder inhalers
  • Pressurised metered dose inhalers and propellants
  • Soft mist inhalers
  • Nebulisers
  • Nasal sprays
  • Aqueous systems
  • Spray drying

Two areas where the underlying physics matters most: the stability of a biologic through aerosolisation and drying, and the reformulation work created by the move to low global warming potential propellants.

Single-particle measurement

The physics is measured, not inferred

Our instruments hold a single droplet or particle in place and record its behaviour directly, at temperatures and humidities set to match the airway rather than the laboratory. Evaporation, composition change, morphology and dissolution are observed across timescales from microseconds to several days in the same experiment, using very little material.

This data is the foundation our simulations are built on: the measurement came first, and the models were built on top of it.

How this adds to standard methods

Cascade impaction and laser diffraction characterise the aerosol as a whole. Single-particle measurement adds what happens to each particle along the way, and our models draw on both.

Published and presented

Our measurements and models are presented at the conferences where inhaled delivery science is discussed, and published with the organisations we work alongside.

  • Evaporation of low global warming potential propellants. Single-droplet measurements that resolve HFA 134a, HFA 152a and HFO 1234ze with microsecond time resolution. Co-authored with scientists from Nanopharm, Aptar Pharma, the US Food and Drug Administration and Theela Life Sciences. Drug Delivery to the Lungs, 2024.
  • Beyond fine particle fraction. Next generation impactor data from four inhaler types coupled to an in silico lung deposition model, with Copley Scientific. Drug Delivery to the Lungs, 2024.
  • In silico tools for inhaled drug development. Respiratory Drug Delivery, 2026, and Inhalation magazine, February 2026.

See all publications and presentations

Capabilities

Single-particle insight

Data on how each droplet or particle evolves under airway temperature and humidity, alongside the whole-aerosol picture from your standard methods.

Rapid processes and long-term changes

Fast evaporation over microseconds and slow solid-state change, captured in a single experiment from very little material. Useful when an active ingredient is scarce or expensive.

Simulation matched to your format

Engines built for the delivery format you are developing: aqueous systems, pressurised metered dose inhalers and dry powders, plus a pulmonary model for regional deposition. A formulation change can be followed from the particle through to the delivered dose.

Inhaled and nasal formats

Dry powder, pressurised metered dose, soft mist, nebulised, nasal sprays and inhaled biologics, including reformulation for low global warming potential propellants.

Three engines, one body of physicsAquaSol, ProVap and PowDisSolve.
Engine Predicts Applies to
AquaSol Aqueous droplet kinetics through drying and inhalation Nebulisers, soft mist inhalers, nasal sprays, spray drying
ProVap Propellant evaporation and the evolution of droplet composition Pressurised metered dose inhalers
PowDisSolve (beta) Aerosol dissolution time from material properties Dry powder inhalers

Because the engines share the same underlying physics, a change in formulation can be followed from the particle through to the delivered dose. That continuity is difficult to achieve when each stage is handled by a separate tool with its own assumptions.

PowDisSolve is in beta and under active development.

How we work with you

Standard measurements.

Single-particle measurements with a fixed scope, so you know before the work starts what will be measured and what you will receive: the data, and a written report on what it means for your programme.

Bespoke support.

For a question that a standard measurement will not answer, we design the exploration around your formulation, run it with our own instruments and simulation engines, and return the data with a written interpretation and what we would do next.

A technology partner.

For a longer programme, we work alongside your team from pre-formulation onwards, alongside your existing analytical, regulatory and manufacturing partners.

Where we fit in a programmeEarly screening, benchtop and preclinical, transfer to manufacture, clinical translation.

Early screening.

Before a candidate is selected, when nothing is committed and the value of narrowing the space is greatest.

Benchtop and preclinical.

Choosing which experiments are worth running, and explaining results that do not behave as expected.

Transfer to manufacture.

Establishing which process and formulation parameters matter most, and how far each can move before performance changes.

Clinical translation.

Regional deposition and delivered dose, estimated from the formulation’s measured behaviour.

Explaining an unexpected result is often as valuable as predicting a new one.

Why Microsol

What reaches the lung is decided by how the particle changes between the device and the airway. We bring single-particle measurement, simulation and formulation expertise together to study that change.

Earlier data. Clearer decisions. Less risk.

Tell us what you are formulating and we will tell you whether we can help.

Contact us